| Mirvetuximab Soravtansine studied in …STUDIED_INderived26 of 26show fewer |
|---|
| → studied in | NCT06890338Phase 2 · recruiting A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. · 26 trials list this drug (14 active) | — | — | Fallopian Tube Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07059845Phase 2 · recruiting A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer · 26 trials list this drug (14 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07825753Phase 2 · not yet recruiting Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer · 26 trials list this drug (14 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06365853Phase 2 · active not recruiting A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression · 26 trials list this drug (14 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07741630Phase 2 · not yet recruiting Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer · 26 trials list this drug (14 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07690332not yet recruiting A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα） · 26 trials list this drug (14 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07218809Phase 3 · recruiting AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer · 26 trials list this drug (14 active) | — | — | Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04606914Phase 2 · recruiting Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer · 26 trials list this drug (14 active) | — | — | Ovarian Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05887609Phase 2 · recruiting An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib · 26 trials list this drug (14 active) | — | — | Malignant Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03832361Phase 2 · recruiting Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer · 26 trials list this drug (14 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03835819Phase 2 · active not recruiting A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) · 26 trials list this drug (14 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06682988Phase 2 · recruiting A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine · 26 trials list this drug (14 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04274426Phase 2 · active not recruiting Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer · 26 trials list this drug (14 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05041257Phase 2 · completed Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers · 26 trials list this drug (14 active) | — | — | Malignant Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05456685Phase 2 · active not recruiting Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer · 26 trials list this drug (14 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04209855Phase 3 · completed A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression · 26 trials list this drug (14 active) | — | — | Malignant Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03552471Phase 1 · completed Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer · 26 trials list this drug (14 active) | — | — | Primary Peritoneal Carcinoma,Ovarian Carcinoma,Endometrial Serous Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04296890Phase 3 · completed A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression · 26 trials list this drug (14 active) | — | — | Malignant Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02606305Phase 1/Phase 2 · completed Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer · 26 trials list this drug (14 active) | — | — | Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02996825Phase 1 · completed Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer · 26 trials list this drug (14 active) | — | — | Breast Carcinoma,Primary Peritoneal Carcinoma,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05622890Phase 3 · unknown A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer · 26 trials list this drug (14 active) | — | — | Malignant Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01609556Phase 1 · completed First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors · 26 trials list this drug (14 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03106077Phase 2 · completed Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer · 26 trials list this drug (14 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02631876Phase 3 · completed A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer · 26 trials list this drug (14 active) | — | — | Primary Peritoneal Carcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03836157Phase 2 · withdrawn Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer · 26 trials list this drug (14 active) | — | — | Endometrial Adenocarcinoma,Endometrial Serous Adenocarcinoma,Endometrial Clear Cell Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03045393Phase 1 · withdrawn Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC · 26 trials list this drug (14 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |